NCT06366347View on ClinicalTrials.gov

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

September 1, 2027

Study Completion Date

March 1, 2029

Conditions
Endometrial CancerRecurrent Endometrial CancerTP53
Interventions
DRUG

Abemaciclib

CDK inhibitor, tablet taken orally per protocol.

DRUG

Letrozole

Aromatase inhibitor, tablet taken orally per protocol.

DRUG

Pembrolizumab

Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.

Trial Locations (6)

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

02035

RECRUITING

Dana-Farber Cancer Institute at Foxborough, Foxborough

01757

RECRUITING

Dana-Farber Cancer Institute at Milford, Milford

02190

RECRUITING

Dana-Farber Cancer Institute at South Shore Hospital, Weymouth

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER